209 related articles for article (PubMed ID: 36359736)
1. CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients.
D'Alterio C; Giardino A; Scognamiglio G; Butturini G; Portella L; Guardascione G; Frigerio I; Montella M; Gobbo S; Martignoni G; Napolitano V; De Vita F; Tatangelo F; Franco R; Scala S
Cells; 2022 Oct; 11(21):. PubMed ID: 36359736
[TBL] [Abstract][Full Text] [Related]
2. A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients.
D'Alterio C; Avallone A; Tatangelo F; Delrio P; Pecori B; Cella L; Pelella A; D'Armiento FP; Carlomagno C; Bianco F; Silvestro L; Pacelli R; Napolitano M; Iaffaioli RV; Scala S
Int J Cancer; 2014 Jul; 135(2):379-90. PubMed ID: 24375277
[TBL] [Abstract][Full Text] [Related]
3. Early pancreatic cancer lesions suppress pain through CXCL12-mediated chemoattraction of Schwann cells.
Demir IE; Kujundzic K; Pfitzinger PL; Saricaoglu ÖC; Teller S; Kehl T; Reyes CM; Ertl LS; Miao Z; Schall TJ; Tieftrunk E; Haller B; Diakopoulos KN; Kurkowski MU; Lesina M; Krüger A; Algül H; Friess H; Ceyhan GO
Proc Natl Acad Sci U S A; 2017 Jan; 114(1):E85-E94. PubMed ID: 27986950
[TBL] [Abstract][Full Text] [Related]
4. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow.
Shakir M; Tang D; Zeh HJ; Tang SW; Anderson CJ; Bahary N; Lotze MT
Pancreas; 2015 May; 44(4):528-34. PubMed ID: 25872129
[TBL] [Abstract][Full Text] [Related]
5. Correlation between CXCR4/CXCR7/CXCL12 chemokine axis expression and prognosis in lymph-node-positive lung cancer patients.
Katsura M; Shoji F; Okamoto T; Shimamatsu S; Hirai F; Toyokawa G; Morodomi Y; Tagawa T; Oda Y; Maehara Y
Cancer Sci; 2018 Jan; 109(1):154-165. PubMed ID: 29032612
[TBL] [Abstract][Full Text] [Related]
6. The nanobody targeting PD-L1 and CXCR4 counteracts pancreatic stellate cell-mediated tumour progression by disrupting tumour microenvironment.
Li Y; Zheng Y; Xu S; Hu H; Peng L; Zhu J; Wu M
Int Immunopharmacol; 2024 May; 132():111944. PubMed ID: 38581990
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma.
McConnell AT; Ellis R; Pathy B; Plummer R; Lovat PE; O'Boyle G
Br J Dermatol; 2016 Dec; 175(6):1210-1220. PubMed ID: 27167239
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of CXCL12, CXCR4, and CXCR7 in patients with breast cancer.
Wu W; Qian L; Chen X; Ding B
Int J Clin Exp Pathol; 2015; 8(10):13217-24. PubMed ID: 26722521
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells.
Qiao N; Wang L; Wang T; Li H
Tumour Biol; 2016 Jun; 37(6):8169-79. PubMed ID: 26715277
[TBL] [Abstract][Full Text] [Related]
10. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.
Daunke T; Beckinger S; Rahn S; Krüger S; Heckl S; Schäfer H; Wesch D; Pilarsky C; Eckstein M; Hartmann A; Röcken C; Wandmacher AM; Sebens S
Front Immunol; 2023; 14():1157397. PubMed ID: 37449210
[TBL] [Abstract][Full Text] [Related]
11. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.
Heinrich EL; Lee W; Lu J; Lowy AM; Kim J
J Transl Med; 2012 Apr; 10():68. PubMed ID: 22472349
[TBL] [Abstract][Full Text] [Related]
12. CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma.
Morita T; Kodama Y; Shiokawa M; Kuriyama K; Marui S; Kuwada T; Sogabe Y; Matsumori T; Kakiuchi N; Tomono T; Mima A; Ueda T; Tsuda M; Yamauchi Y; Nishikawa Y; Sakuma Y; Ota Y; Maruno T; Uza N; Nagasawa T; Chiba T; Seno H
Cancer Res; 2020 Oct; 80(19):4058-4070. PubMed ID: 32606001
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8
Yamaki S; Yanagimoto H; Tsuta K; Ryota H; Kon M
Int J Clin Oncol; 2017 Aug; 22(4):726-733. PubMed ID: 28314962
[TBL] [Abstract][Full Text] [Related]
14. PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications.
Luchini C; Cros J; Pea A; Pilati C; Veronese N; Rusev B; Capelli P; Mafficini A; Nottegar A; Brosens LAA; Noë M; Offerhaus GJA; Chianchiano P; Riva G; Piccoli P; Parolini C; Malleo G; Lawlor RT; Corbo V; Sperandio N; Barbareschi M; Fassan M; Cheng L; Wood LD; Scarpa A
Hum Pathol; 2018 Nov; 81():157-165. PubMed ID: 30031096
[TBL] [Abstract][Full Text] [Related]
15. High expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in renal cell carcinoma.
Wang L; Chen W; Gao L; Yang Q; Liu B; Wu Z; Wang Y; Sun Y
World J Surg Oncol; 2012 Oct; 10():212. PubMed ID: 23039915
[TBL] [Abstract][Full Text] [Related]
16. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
Khare T; Bissonnette M; Khare S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
[TBL] [Abstract][Full Text] [Related]
17. CXCL12 chemokine expression suppresses human pancreatic cancer growth and metastasis.
Roy I; Zimmerman NP; Mackinnon AC; Tsai S; Evans DB; Dwinell MB
PLoS One; 2014; 9(3):e90400. PubMed ID: 24594697
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Impact of CXCR7 and CXCL12 Expression in Patients with Esophageal Adenocarcinoma.
Goto M; Shibahara Y; Baciu C; Allison F; Yeung JC; Darling GE; Liu M
Ann Surg Oncol; 2021 Sep; 28(9):4943-4951. PubMed ID: 33709176
[TBL] [Abstract][Full Text] [Related]
19. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.
Daniel SK; Seo YD; Pillarisetty VG
Semin Cancer Biol; 2020 Oct; 65():176-188. PubMed ID: 31874281
[TBL] [Abstract][Full Text] [Related]
20. CXCR4-CXCL12-CXCR7, TLR2-TLR4, and PD-1/PD-L1 in colorectal cancer liver metastases from neoadjuvant-treated patients.
D'Alterio C; Nasti G; Polimeno M; Ottaiano A; Conson M; Circelli L; Botti G; Scognamiglio G; Santagata S; De Divitiis C; Nappi A; Napolitano M; Tatangelo F; Pacelli R; Izzo F; Vuttariello E; Botti G; Scala S
Oncoimmunology; 2016; 5(12):e1254313. PubMed ID: 28123896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
